GLP-1 Medications and Mental Health: What You Should Know

What Are GLP-1 Medications and How Do They Work?

GLP-1 stands for glucagon-like peptide-1, a hormone your gut releases after eating. GLP-1 receptor agonists are medicines that mimic this hormone. Tirzepatide acts on GLP-1 receptors and on a second hormone receptor called GIP.

These medicines work in several ways:

• Helping the pancreas release insulin when blood sugar is high
• Slowing how quickly the stomach empties
• Acting on appetite-regulating areas of the brain to increase feelings of fullness

In the United States, FDA-approved uses include improving blood sugar control in type 2 diabetes, chronic weight management for people with obesity or overweight, and—for certain products—reducing cardiovascular risk and other specific conditions.

No GLP-1 medication is FDA-approved to treat depression, anxiety, addiction, or any other psychiatric disorder.

Appetite, Fullness, and Reward

GLP-1 receptors are found not only in the gut but also in brain regions involved in hunger, fullness, and reward. Many people taking these medications describe less “food noise”—fewer intrusive thoughts about food and reduced cravings.

Because the brain's reward system is involved in many behaviors, researchers are studying whether these effects extend beyond food. For now, most of that understanding comes from animal studies and early human research.

Depression, Anxiety, and Emotional Well-Being

Some people report improved mood, confidence, or energy while taking a GLP-1 medication. Others notice no change, and some experience fatigue, low mood, or irritability—sometimes related to side effects, eating much less, or the stress of physical change.

Large studies have not shown that GLP-1 medications reliably improve or worsen depression or anxiety overall. Any improvement a person notices may reflect better blood sugar control, weight changes, improved physical health, or other life factors rather than a direct antidepressant effect.

GLP-1 Medications and Addictive Behaviors

One of the most active areas of research is whether GLP-1 medications reduce alcohol use or other substance use.

Early findings are interesting but preliminary:

• Animal studies show reduced alcohol intake with GLP-1 receptor activation.
• A small randomized trial of exenatide in alcohol use disorder did not reduce heavy drinking overall, although a subgroup with obesity appeared to benefit.
• A small 2025 randomized trial found that low-dose semaglutide reduced some measures of alcohol consumption and craving over nine weeks.
• Observational studies have reported associations with lower rates of alcohol- and substance-related problems, but these studies cannot prove cause and effect.

What Regulators Found About Suicidal Thoughts

In 2023, reports of suicidal thoughts in people taking GLP-1 medications prompted reviews by the FDA and the European Medicines Agency (EMA).

• In January 2024, the FDA reported that its preliminary evaluation had not found evidence that these medicines cause suicidal thoughts or actions.
• In April 2024, the EMA's safety committee concluded the available evidence did not support a causal link.
• On January 13, 2026, the FDA requested removal of suicidal ideation and behavior warnings from Saxenda, Wegovy, and Zepbound labeling following a review that found no increased risk.

This is reassuring, but it does not mean every individual will feel emotionally well on these medications. People with a history of depression, suicidal thoughts, or bipolar disorder were often underrepresented in clinical trials.

If you ever have thoughts of harming yourself, seek help immediately—regardless of what medication you take.

Weight Changes, Body Image, and Psychological Well-Being

Weight loss can bring real physical benefits and, for some people, improved self-esteem. It can also bring unexpected emotional challenges, such as:

• Changing relationships with food, which may have served as a source of comfort or social connection
• Increased attention from others about one's body
• Worry about regaining weight if the medication is stopped
• Persistent dissatisfaction with body image even after weight changes

These experiences are common and understandable. Talking about them openly with a clinician can help.

Disordered Eating, Nutrition, and Dehydration

Because GLP-1 medications strongly reduce appetite, they can unintentionally reinforce restrictive eating. This is an important consideration for anyone with a current or past eating disorder.

Other potential concerns include:

• Eating too little protein, fiber, or overall nutrition
• Loss of muscle along with fat
• Nausea, vomiting, or diarrhea, which can lead to dehydration
• Gallbladder problems and, rarely, pancreatitis
• Use of unapproved or compounded products, which the FDA has warned can carry quality risks and dosing errors

Considerations If You Take Psychiatric Medications

Whether a GLP-1 medication fits safely with your psychiatric medications depends on your individual situation. Your prescribers should review possible interactions with your full medication list and plan any monitoring you may need. Points worth discussing include:

• Absorption: GLP-1 medications slow stomach emptying, which may change how some oral medications are absorbed, especially when starting or increasing the dose.
• Dehydration: vomiting or diarrhea can affect medications with narrow safety ranges, such as lithium, so monitoring may be needed.
• Appetite and weight: some psychiatric medications increase appetite or weight, and GLP-1 medications are sometimes discussed in that context by a patient's medical team.
• Coordination: make sure every prescriber—including your psychiatric clinician—has your complete, current medication list.

Do not stop or change any psychiatric medication on your own because you started a GLP-1 medication.

When to Contact Your Healthcare Provider

Reach out to your prescriber or psychiatric clinician if you notice:

• New or worsening depression, anxiety, irritability, or loss of interest
• Changes in sleep, energy, or concentration that persist
• Restrictive eating, purging, or intense fear of eating
• Side effects from psychiatric medications that seem new or stronger

Seek urgent medical evaluation—call your prescriber right away, go to an emergency department, or call 911—if you have severe or persistent abdominal pain (with or without vomiting), are unable to keep fluids down, or have signs of significant dehydration such as dizziness, confusion, or very little urination.

If you are in crisis or thinking about suicide, call or text 988 (the Suicide & Crisis Lifeline) or call 911. Do not wait for a scheduled appointment.

Key Takeaways

• GLP-1 medications act on appetite and reward pathways in the brain as well as the gut.
• They are not FDA-approved treatments for any psychiatric condition.
• Research on addictive behaviors is promising but preliminary.
• The FDA requested removal of suicidal ideation and behavior warnings from Saxenda, Wegovy, and Zepbound labeling following a review that found no increased risk.
• Nutrition, eating-disorder history, dehydration, and medication interactions deserve attention.
• Mood changes of any kind are worth discussing with your clinician.